血清中期因子水平在非小细胞肺癌中的价值研究

摘要

Objective To detect the levels of midkine (MK) in the serum of patients with non-small cell lung cancer (NSCLC), and to explore the relationship between MK levels and NSCLC. Methods Enzyme-linked immuno-sorbent assay (ELISA) was used to detect the levels of serum MK in 52 patients with NSCLC, 52 patients with pneu-monia and 52 healthy people. The relationships between MK levels and clinical pathological characteristics, treatment effect in non-small cell lung cancer were analyzed. Results MK levels were significantly higher in NSCLC patients than patients with pneumonia and healthy people (P<0.05), in smoking patients than non-smoking patients (P<0.05), and in NSCLC patients of stageⅢ~Ⅳthan NSCLC patients of stageⅠ~Ⅱ(P<0.05). There was no significant differ-ence in MK levels between adenocarcinoma and squamous carcinoma (P>0.05). MK levels of patients who have lymph node metastasis were higher than patients with no lymph node metastasis (P<0.05). In the 48 NSCLC patients, Mk levels were significantly decreased after treatment, showing statistically significant difference with those before treatment (P<0.05). Conclusion The midkine level of patients with NSCLC has close relationships with pathologi-cal type, clinical stage and smoking, which is a reliable indicator for clinical therapeutic effect.%目的 检测非小细胞肺癌(NSCLC)患者血清中期因子(Midkine,MK)的水平,探讨其与NSCLC关系.方法 采用酶联免疫吸附试验(ELISA)分别测定52例NSCLC患者、52例肺炎患者和52例健康对照者的血清MK的水平,探讨其与NSCLC的临床病理特征和治疗效果关系.结果 NSCLC患者血清MK水平明显高于肺炎组和健康对照组,差异具有统计学意义(P<0.05);吸烟的患者血清MK水平明显高于不吸烟患者(P<0.05).NSCLC患者血清Ⅲ~Ⅳ期MK水平高于Ⅰ~Ⅱ期(P<0.05),腺癌MK水平与鳞癌比较差异无统计学意义(P>0.05).有淋巴结转移的NSCLC患者MK水平明显高于无淋巴结转移者(P<0.05).同时,对其中的48例NSCLC患者进行治疗后血清MK水平检测,与治疗前比较血清MK明显降低,差异具有统计学意义(P<0.05).结论 NSCLC患者血清MK水平与其病理类型、临床分期密切相关,也与患者本身是否吸烟有联系,其是判断临床治疗效果的可靠指标.